TITLE

Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza

AUTHOR(S)
Ariano, Robert E.; Sitar, Daniel S.; Zelenitsky, Sheryl A.; Zarychanski, Ryan; Pisipati, Amarnath; Ahern, Stéphane; Kanji, Salmaan; Rello, Jordi; Kumar, Anand
PUB. DATE
March 2010
SOURCE
CMAJ: Canadian Medical Association Journal;3/9/2010, Vol. 182 Issue 4, p357
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Whether the enteric absorption of the neuraminidase inhibitor osel tamivir is impaired in critically ill patients is unknown. We documented the pharmacokinetic profile of oseltamivir in pa tients admitted to intensive care units (ICUs) with suspected or confirmed pandemic (H1N1) influenza. Methods: We included 41 patients 18 years of age and older with suspected or confirmed pandemic (H1N1) influ - enza who were admitted for ventilatory support to nine ICUs in three cities in Canada and Spain. Using tandem mass spectrometry, we assessed plasma levels of oseltami - vir free base and its active metabolite carboxylate at baseline (before gastric administration of the drug) and at 2, 4, 6, 9 and 12 hours after the fourth or later dose. Results: Among the 36 patients who did not require dialysis, the median concentration of oseltamivir free base was 10.4 (interquartile range [IQR] 4.8-14.9) μg/L; the median concentration of the carboxylate metabolite was 404 (IQR 257-900) μg/L. The volume of distribution of the carboxylate metabolite did not increase with increasing body weight (R2 = 0.00, p = 0.87). The rate of elimination of oseltamivir carboxylate was modestly correlated with estimations of creatinine clearance (R2 = 0.27, p < 0.001). Drug clearance in the five patients who required continuous renal replacement therapy was about one-sixth that in the 36 patients with relatively normal renal function. Interpretation: Oseltamivir was well absorbed enterically in critically ill patients admitted to the ICU with suspected or confirmed pandemic (H1N1) influenza. The dosage of 75 mg twice daily achieved plasma levels that were comparable to those in ambulatory pa tients and were far in excess of concentrations required to maximally inhibit neuramini dase activity of the virus. Adjustment of the dosage in patients with renal dysfunction requiring continuous renal replacement therapy is appropriate; adjustment for obesity does not appear to be necessary.
ACCESSION #
48490515

 

Related Articles

  • Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. Campbell, Alexia; Rodin, Rachel; Kropp, Rhonda; Yang Mao; Zhiyong Hong; Vachon, Julie; Spika, John; Pelletier, Louise // CMAJ: Canadian Medical Association Journal;3/9/2010, Vol. 182 Issue 4, p349 

    Background: We describe the disease characteristics and outcomes, including risk factors for admission to intensive care unit (ICU) and death, of all patients in Canada admitted to hospital with pandemic (H1N1) influenza during the first five months of the pandemic. Methods: We obtained data for...

  • Case Fatality Rates Based on Population Estimates of Influenza-Like Illness Due to Novel H1N1 Influenza: New York City, May-June 2009. Hadler, James L.; Konty, Kevin; McVeigh, Katharine H.; Fine, Anne; Eisenhower, Donna; Kerker, Bonnie; Thorpe, Lorna // PLoS ONE;2010, Vol. 5 Issue 7, p1 

    Background: The public health response to pandemic influenza is contingent on the pandemic strain's severity. In late April 2009, a potentially pandemic novel H1N1 influenza strain (nH1N1) was recognized. New York City (NYC) experienced an intensive initial outbreak that peaked in late May,...

  • Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein.  // PLoS ONE;2009, Vol. 4 Issue 11, p1 

    The article discusses a study which examined the activity of DAS181 against several pandemic influenza A (H1N1) virus isolates in MDCK cells, differentiated primary human respiratory tract culture, ex-vivo human bronchi tissue and mice. As explained, DAS181 (Fludase) is a sialidase fusion...

  • Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Mexico. Ramirez-Gonzalez, José Ernesto; Gonzalez-Duran, Elizabeth; Alcantara-Perez, Patricia; Wong-Arambula, Claudia; Olivera-Diaz, Hiram; Cortez-Ortiz, Iliana; Barrera-Badillo, Gisela; Nguyen, Ha; Gubareva, Larisa; Lopez-Martinez, Irma; Díaz-Quiñonez, Jose Alberto; Lezana-Fernández, Miguel Angel; Gatell-Ramírez, Hugo Lopez; Villalobos, Jose Angel Cordova; Hernández-Avila, Mauricio; Alpuche-Aranda, Celia // Emerging Infectious Diseases;Feb2011, Vol. 17 Issue 2, p283 

    During May 2009-April 2010, we analyzed 692 samples of pandemic (H1 N1 ) 2009 virus from patients in Mexico. We detected the H275Y substitution of the neuraminidase gene in a specimen from an infant with pandemic (HIN1) 2009 who was treated with oseltamivir. This virus was susceptible to...

  • Antiviral Recommendations for H1N1. Elliott, William T. // Neurology Alert;Oct2009 Pharmacology Watch, p1 

    The article reports that a global alert and response have been issued by the World Health Organization (WHO) regarding the use of antivirals for pandemic H1N1 flu. According to the WHO, antivirals should be used to avoid severe illnesses and death in children and adults. Patients who have...

  • Swine Flu. Calisher, Charles H. // Croatian Medical Journal;Aug2009, Vol. 50 Issue 4, p412 

    The author offers information on the swine flu which is declared as the cause of a Phase Six global pandemic by the World Health Organization (WHO). He warns that surveillance must be maintained even if the virus seems to have disappeared as it has the ability to resurface. The author notes that...

  • Positive selection on hemagglutinin and neuraminidase genes of H1N1 influenza viruses. Wenfu Li; Weifeng Shi; Huijie Qiao; Ho, Simon Y. W.; Arong Luo; Yanzhou Zhang; Chaodong Zhu // Virology Journal;2011, Vol. 8 Issue 1, p183 

    Background: Since its emergence in March 2009, the pandemic 2009 H1N1 influenza A virus has posed a serious threat to public health. To trace the evolutionary path of these new pathogens, we performed a selection-pressure analysis of a large number of hemagglutinin (HA) and neuraminidase (NA)...

  • Predictors of fatality in pandemic influenza a (H1N1) virus infection among adults. Ergönül, Önder; Alan, Servet; Ak, Öznur; Sargın, Fatman; Kantürk, Arzu; Gündüz, Alper; Engin, Derya; Öncül, Oral; Balkan, Ilker Inanc; Ceylan, Bahadir; Benzonana, Nur; Yazıcı, Saadet; Şimşek, Funda; Uzun, Nuray; İnan, Asuman; Gulhan, Eren; Ciblak, Meral; Midilli, Kenan; Ozyurt, Mustafa; Badur, Selim // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background The fatality attributed to pandemic influenza A H1N1 was not clear in the literature. We described the predictors for fatality related to pandemic influenza A H1N1 infection among hospitalized adult patients. Methods This is a multicenter study performed during the pandemic influenza...

  • Characterization of Neuraminidases from the Highly Pathogenic Avian H5N1 and 2009 Pandemic H1N1 Influenza A Viruses. Jia Wu; Fengwei Zhang; Maorong Wang; Chunqiong Xu; Jingdong Song; Jianfang Zhou; Xiaojing Lin; Yonghui Zhang; Xiaobing Wu; Wenjie Tan; Jian Lu; Honglan Zhao; Jimin Gao; Ping Zhao; Jianxin Lu; Yue Wang // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    To study the precise role of the neuraminidase (NA), and its stalk region in particular, in the assembly, release, and entry of influenza virus, we deleted the 20-aa stalk segment from 2009 pandemic H1N1 NA (09N1) and inserted this segment, now designated 09s60, into the stalk region of a highly...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics